An intronic variant in PTEN is not associated with prostate cancer risk.
Nathanson
K L
KL
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-6021, USA.
Omaruddin
R
R
Malkowicz
S B
SB
Rebbeck
T R
TR
D017677:Age Distribution; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D016022:Case-Control Studies; D015331:Cohort Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016017:Odds Ratio; D051059:PTEN Phosphohydrolase; D010744:Phosphoric Monoester Hydrolases / Q000032:analysis / Q000235:genetics*; D011110:Polymorphism, Genetic; D015995:Prevalence; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000235:genetics*; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D025521:Tumor Suppressor Proteins
D014408:Biomarkers, Tumor; D025521:Tumor Suppressor Proteins; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human